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To investigate the aetiological role of human papillomavirus (HPV) in breast cancer, we examined the presence, genotype, viral load,
and physical status of HPV in 124 Japanese female patients with breast carcinoma. Human papillomavirus presence was examined by
PCR using SPF10 primers, and primer sets targeting the E6 region of HPV-16, -18, and -33. The INNO-LiPA HPV genotyping kit was
used to determine genotype. Human papillomavirus DNA was detected in 26 (21%) breast carcinomas. The most frequently
detected HPV genotype was HPV-16 (92%), followed by HPV-6 (46%), HPV-18 (12%), and HPV-33 (4%). In 11 normal epithelium
specimens adjacent to 11 HPV-16-positive carcinomas, 7 were HPV-16-positive. However, none of the normal breast tissue
specimens adjacent to HPV-negative breast carcinomas were HPV-positive. The real-time PCR analysis suggested the presence of
integrated form of viral DNA in all HPV-16-positive samples, and estimated viral load was low with a geometric mean of 5.4 copies
per 10
4 cells. In conclusion, although HPV DNA was detected in 26 (21%) breast carcinomas and, in all HPV-16-positive cases, the
HPV genome was considered integrated into the host genome, their low viral loads suggest it is unlikely that integrated HPV is
aetiologically involved in the development of Japanese breast carcinomas that we examined.
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Breast cancer is one of the most prevalent malignancies through-
out the world. It is the leading female cancer worldwide and comes
second after stomach cancer in Japan (Parkin et al, 1999). Recent
studies have suggested that some types of viruses, especially
human papillomavirus (HPV), might be involved in the patho-
genesis of breast cancer (Liu et al, 2001; Tsai et al, 2007).
Molecular and epidemiological studies have shown that a
persistent infection with high-risk HPV is the most important
risk factor for both cervical cancer and its precursors (Cuschieri
et al, 2005; Steenbergen et al, 2005). A number of studies have
reported HPV DNA detection in extragenital cancers, although the
aetiological involvement of HPV in those malignancies is still
controversial (Gillison and Shah, 2003). Recently, it has been
shown that HPV types 16 and 18 can immortalize normal breast
epithelium (Band et al, 1990; Wazer et al, 1995). This raised the
possibility that HPV may be aetiologically related to some cases of
breast cancer. However, unlike cervical carcinoma, which is almost
always associated with HPV, the causal role of HPV infection in the
development of breast carcinoma remains controversial.
Di Lonardo et al (1992) were the first to report the relationship
between HPV and breast cancer, demonstrating HPV-16 DNA in
29.4% of breast carcinomas, using PCR with primer sets specific
for HPV-11, -16, and -18 genotypes. A study in Norway, which
used primers specific for HPV-11, -16, -18, and -33, in addition to
GP5þ/6þ primers, detected HPV in 46% of breast carcinomas. In
this previous study, only HPV-16 was detected (Hennig et al,
1999). Another European study showed the presence of high-risk
HPVs in 15% of invasive breast carcinomas in Greece (Kroupis
et al, 2006). A Chinese study also found that 35% of breast
carcinomas examined were HPV-16-positive, using type-specific
primers for HPV-16 and consensus primers for the HPV L1 gene
(Liu et al, 2001). In addition, a study in Korea reported HPV DNA
presence in breast carcinomas (6.5%) but not in intraductal
papilloma (Choi et al, 2007). Furthermore, a study in Brazil
demonstrated HPV-16 and HPV-18 in 14 and 10% of breast
carcinomas, respectively, using genotype-specific primers (Damin
et al, 2004). In addition, an Australian study reported by Kan et al
(2005) used primers specific for HPV-16, -18, and -33, and
demonstrated the presence of HPV-18 in 48% of breast cancer
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sspecimens. However, neither HPV-16 nor HPV-33 was detected in
their study. Another study conducted in China and Japan, which
used primers for HPV-16, -18, and -33, detected HPV-33 in 41.7
and 11.1% of breast carcinomas in two countries, respectively (Yu
et al, 1999). By examining nipple and breast cancer specimens, de
Villiers et al (2005) detected high-risk and low-risk HPVs in 86%
of them. They used GP5þ/6þ, FAP primers for cutaneous-type
HPVs, and CP primers. In contrast, several other studies failed to
demonstrate HPV DNA in tumors of the breast (Wrede et al, 1992;
Lindel et al, 2007).
In malignant transformation of the uterine cervical epithelia,
the integration of high-risk HPV DNA into the host genome is
considered an important step (zur Hausen, 1991). Viral
DNA integration leads to frequent disruption of the HPV-16 E2
gene (Kalantari et al, 1998), a negative regulator of the
E6/E7 promoter, resulting in the upregulation of the transcription
of the E6 and E7 oncogenes. Human papillomavirus-16 E6
and E7 oncogenes interfere with the normal cell cycle by
targeting the p53 and pRb tumor suppressor proteins, respectively
(Vousden, 1993). Human papillomavirus-16 DNA integration
into the host genome possibly provides a selective growth
advantage to the host cell (Jeon et al, 1995; Jeon and
Lambert, 1995).
When considering the aetiological role of HPV in non-genital
cancers, an important question that should be addressed is the
integration of HPV into the host genome. Venuti et al (2000) found
that 43% of HPV-16-positive laryngeal carcinomas had HPV-16
DNA integrated into the host genome. Koskinen et al (2003) also
reported that 65% of HPV-16-positive head and neck carcinomas
had integrated HPV-16 DNA. Recent studies conducted by our
laboratory also showed that most HPV-16-positive esophageal and
lung carcinomas had integrated HPV-16 DNA (Aguayo et al, 2007;
Shuyama et al, 2007). To our knowledge, however, none of the
published studies have investigated the possibility of integration of
HPV in breast cancer tissues.
Considering the controversial reports on the aetiology of HPV in
breast carcinomas, the aim of this study was to examine the
presence, genotype, viral load, and physical status of HPV,
particularly high-risk HPV, among breast carcinomas in Japan,
where breast cancer risk is low when compared with Europe and
North America (Parkin et al, 2002), and to investigate its
aetiological role.
MATERIALS AND METHODS
Study subjects
A total of 124 formalin-fixed and paraffin-embedded breast cancer
specimens consisting of 42 cases from Sagara Hospital (Kagoshima,
Japan), diagnosed during the period between 2000 and 2001, and
82 cases from Kagoshima University Hospital (Kagoshima, Japan),
diagnosed during the period between 2000 and 2006, were
examined in this study. In addition, as positive controls, we
examined formalin-fixed and paraffin-embedded specimens from
six cervical cancer cases diagnosed at Kagoshima University
Hospital. Clinicopathological information, including the expres-
sion of oestrogen and progesterone receptors, reproductive
histories, and family history of breast cancer, was obtained from
medical and pathological records. Histological classification for
breast cancer was made using the guidelines determined by the
Japanese Breast Cancer Society (2004). With regard to cervical
cancer, we also applied the guidelines determined by the Japan
Society of Obstetrics and Gynaecology, The Japanese Society of
Pathology, and the Japan Radiological Society (1999). The
Institutional Review Board of Kagoshima University Graduate
School of Medical and Dental Sciences (Japan) approved this
study.
DNA extraction
Sections of 10mm thickness were cut and collected in sterile tubes.
To avoid contamination between samples, a cutter blade was
changed between each sample cutting. For DNA extraction from
paraffin-embedded tissue, each sample was treated with 0.8ml of
lemosol and 0.2ml of ethanol, and subsequently washed with 1ml
of ethanol. After centrifugation and air-drying, the pellet was
resuspended in digestion buffer (50mM Tris-HCl pH 8.0, 1mM
EDTA, pH 8.0, and 0.5% Tween 20) containing 200mgml
 1 of
proteinase K (Invitrogen Corp., Carlsbad, CA, USA) and incubated
for 24h at 561C. The solution was then heated at 1001C for 10min,
followed by phenol–chloroform extraction and ethanol precipita-
tion of DNA. DNA quality and the absence of PCR inhibitors
in samples were tested by PCR for b-globin using PCO3
50-ACACAACTGTGTTCACTAGC-30 and PCO4 50-CAACTTCATC
CACGTTCACC-30 primers under the following PCR conditions:
initial denaturation at 951C for 15min, 40 cycles with the cycling
profile of 951C for 1min, 521C for 1min, 721C for 1min, and final
extension for 5min at 721C.
HPV detection and genotyping
The HPV genome was detected with a broad-spectrum SPF10-
biotinylated primer PCR. The PCR products, 65bp of the L1 gene,
were run on a 4% agarose gel and visualized with ethidium
bromide staining by electrophoresis. Human papillomavirus
typing of the HPV DNA-positive samples was performed using
the INNO-LiPA HPV Genotyping v2 test (Innogenetics, Ghent,
Belgium) (Ketler et al, 1999). In addition, we also analysed all
samples through additional type-specific PCR using primer sets
targeting the E6 regions of HPV-18 and HPV-33 (Yu et al, 1999).
These type-specific primers could detect 140bp in the E6 region of
HPV-18 and HPV-33.
Paraffin sections without tissue and distilled water were used as
negative controls for procedures of DNA extraction and PCR,
respectively. Full genomes of HPV-16 and HPV-18 cloned in
pUC19 plasmid (kindly given by Dr Massimo Tommasino, IARC,
Lyon, France), and HPV-33-positive cervical cancer specimens
were used as positive controls for amplification.
Quantitative real-time PCR
To determine the presence and physical status, as well as estimate
the viral load of HPV-16, real-time PCR was performed with the
ABI Prism 7700 Sequence Detection System (Applied Biosystems,
Foster City, CA, USA) and 2  QuantiTect SYBR Green PCR kit
(Qiagen, Hilden, Germany). The HPV-16 primers for E6 ORF
amplification were as follows: E6F: 50-GAGAAACTGCAATGTTT
CAGGACC-30 and E6R: 50-TGTATAGTTGTTTGCAGCTCTGTGC-30.
The HPV-16 primers for E2 ORF amplification were as follows:
E2F: 50-AACGAAGTATCCTCTCCTGAAATTATTAG-30 and E2R:
50-CCAAGGCGACGGCTTTG-30. The PCR amplification conditions
were 2min at 501C, 15min at 951C, and a two-step cycle of 951C for
15s, and 601C for 60s for a total of 40 cycles (Peitsaro et al, 2002).
The sizes of the E6 and E2 products were 81 and 76bp,
respectively.
Serial dilutions of the full-length HPV-16 genome, containing
equivalent amounts of E2 and E6 genes from 86 to 862 million
copies per reaction, served as a standard control. Numbers of the
threshold cycle obtained from E2 PCR and E6 PCR were equivalent
in each run. Linear plots of the log of copy number vs numbers of
threshold cycle were consistently obtained for both genes.
Real-time PCR for the b-globin gene was performed by the
2  QuantiTect SYBR Green PCR kit (Qiagen) using PC03/PC04 to
adjust the differences in the amount of input genomic DNA
between samples. A seven-fold dilution series of a human DNA
control (Dynal, UK Ltd, Bromborough, Wirral, Merseyside, UK)
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swas used to generate the standard curve. The amount of b-globin
DNA present in each sample was divided by the weight of one
genome equivalent (that is, 6.6pg per cell) and a factor of 2 (as
there are two copies of b-globin DNA/genome equivalent or cell) to
obtain the number of genome equivalents or cell in the sample.
Viral loads in each specimen were expressed as the number of HPV
copies per 10
4 cells.
Immunohistochemistry for HER2/neu overexpression
HER2/neu overexpression was examined, using the Hercep Test kit
(Dako, Carpinteria, CA, USA) following the manufacturer’s
instructions. Control cell lines provided by the manufacturer
(Dako) were used as negative and positive controls. The data on its
oevererexpression for 17 HPV-positive breast carcinomas (16
invasive carcinomas and 1 non-invasive carcinoma) and 42 HPV-
negative carcinomas (40 invasive carcinomas and 2 non-invasive
carcinoma) were obtained from medical records. In the HPV-
positive cases, HER2/neu expression was additionally examined in
seven cases. Following the Hercep Test criteria, the immuno-
reaction was scored as follows: 3þ, complete and intense
membrane staining of 410% tumor cells; 2þ, complete but
moderate staining of 410% tumor cells; 1þ, weak and incomplete
staining in 410% tumor cells; and 0, no membrane staining
or staining in o10% tumor cells. We defined cases with a score
3þ as HER2/neu overexpression.
Statistical analysis
Fisher’s exact test was conducted to test statistical significance
using STATA (version 8.5, Stata Corporation, College Station,
TX, USA). All the P-values presented are two-sided.
RESULTS
We examined 124 female breast cancer cases, aged from 23 to 90
years with a mean of 55 years. b-globin amplification was carried
out to check the quality of DNA in formalin-fixed and paraffin-
embedded specimens. All samples were positive for b-globin gene
amplification, indicating that DNA was available for molecular
analysis.
First, we examined all samples using novel, broad-spectrum
SPF10 primers for HPV detection. Human papillomavirus DNA
was positive in 24 out of 124 (19%) breast cancer specimens. As an
alternative approach, we examined all specimens using primer sets
targeting the E6 region of HPV genotypes 16, 18, and 33. By using
genotype-specific primers, HPV-16 was detected in two new cases.
No additional cases of HPV-18 and HPV-33 were detected by
genotype-specific approach. Thus, in total, HPV DNA was detected
in 26 (21%) breast cancer specimens.
Table 1 presents the HPV frequency according to various
clinicopathological features. There was no significant difference in
the HPV detection rate between invasive and non-invasive
carcinomas. Among invasive carcinomas, HPV DNA was detected
in 7 (20%) papillotubular carcinomas, 5 (29%) solid-tubular
carcinomas, and 9 (20%) scirrhous carcinomas. Human papillo-
mavirus detection rates were not different among those histolo-
gical types of invasive carcinomas (data not shown in the table).
The presence of HPV was not related to the expression of
oestrogen and progesterone receptors. Among the 12 patients with
bilateral breast carcinomas, we could obtain breast cancer speci-
mens from the other side from 2 HPV-positive and 2 HPV-negative
cases. We also examined the presence of HPV DNA in these
specimens by the same PCR methods. However, none of them was
HPV-positive.
HER2/neu expression was examined in 23 invasive and 1 non-
invasive HPV-positive breast carcinomas. Three (13%) invasive
carcinomas had its overexpression (score of 3þ) and the non-
invasive carcinoma had no HER2/neu overexpression (score¼1).
On the other hand, in HPV-negative carcinomas, its overexpres-
sion was observed in 6 out of 40 (15%) invasive carcinomas, and in
1 out of 2 non-invasive carcinomas. Neither in HPV-positive nor in
Table 1 Frequency of HPV-positive cases by clinicopathological factors
All cases HPV-negative HPV-positive
N (%) N (%) N (%) P-value
a
Number of cases 124 (100) 98 (79) 26 (21)
Tumor depth 0.279
Non-invasive 25 (100) 22 (88) 3 (12)
Invasive 99 (100) 76 (77) 23 (23)
Age (years) 0.966
o40 15 (100) 12 (80) 3 (20)
40–49 37 (100) 28 (76) 9 (24)
50–59 27 (100) 22 (81) 5 (19)
60– 45 (100) 36 (80) 9 (20)
Family history of breast cancer
b 1.000
No 110 (100) 87 (79) 23 (21)
Yes 12 (100) 10 (83) 2 (17)
Have married
b 1.000
No 7 (100) 6 (86) 1 (14)
Yes 115 (100) 91 (79) 24 (21)
Number of children
b 0.613
None 22 (100) 19 (86) 3 (14)
1 15 (100) 13 (87) 2 (13)
2 49 (100) 36 (73) 13 (27)
3– 35 (100) 28 (80) 7 (20)
Tumor size 0.126
(P for trend ¼0.321)
Tis or T1mic 28 (100) 24 (86) 4 (14)
T1a 10 (100) 9 (90) 1 (10)
T1b 16 (100) 14 (88) 2 (12)
T1c 33 (100) 22 (67) 11 (33)
T2 27 (100) 19 (70) 8 (30)
T3  10 (100) 10 (100) 0 (0)
Lymph vessel invasion 0.612
No 93 (100) 72 (77) 21 (23)
Yes 31 (100) 26 (84) 5 (16)
Vascular invasion
b 0.343
No 116 (100) 90 (78) 26 (22)
Yes 7 (100) 7 (100) 0 (0)
Lymph node metastasis
b 1.000
No 99 (100) 78 (79) 21 (21)
Yes 24 (100) 19 (79) 5 (21)
Oestrogen receptor expression
b 1.000
No 24 (100) 19 (79) 5 (21)
Yes 88 (100) 68 (77) 20 (23)
Progesterone receptor expression
b 1.000
No 37 (100) 29 (78) 8 (22)
Yes 74 (100) 57 (77) 17 (23)
Breast cancer at both sides
b 0.233
No 110 (100) 88 (80) 22 (20)
Yes 12 (100) 8 (67) 4 (33)
HPV¼human papillomavirus.
aP-values for heterogeneity were obtained by Fisher’s
exact test.
bTotal number of cases did not add up to 124 because the cases without
relevant information were excluded from analysis.
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sHPV-negative carcinomas HER2/neu overexpression was asso-
ciated with any clinicopathological factors, including tumor size,
lymph vessel invasion, vascular invasion, and lymph node
metastasis (data not shown).
The most prevalent HPV type was HPV-16, which was detected
in 24 (92%) out of 26 HPV-positive cases, using the INNO-LiPA
HPV genotyping assay and the type-specific approach (Table 2).
Among them, three cases (BC-72, BC-78, and BC-112) were
identified as HPV-16-positive only by the PCR with HPV-16-
specific primers. Other HPV types, identified only by the INNO-
LiPA HPV genotyping assay, were HPV-6 in 12 (50%) cases,
HPV-18 in 3 (12%) cases, HPV-51 in 2 (8%) cases, and HPV-33
in 1 (4%) case. Multiple infections were found in 12 (46%)
HPV-positive cases (Table 2).
All of the HPV-16-positive breast carcinoma specimens were
subjected to quantitative real-time PCR analysis to determine the
viral load and physical status of HPV-16. The HPV-16 copy
numbers of E6 and E2 genes per 10
4 cells, the ratios of E2 to E6,
and the viral physical status are compiled in Table 2. The
geometric mean of HPV-16 copies per 10
4 cells was 5.4 in cancers
of the breast and 130480 in cancers of the uterine cervix. In 19
(95%) breast carcinoma cases, E2 DNA was not detected, and in
1 (5%) case, E2 DNA was detected, but the E2/E6 ratio was less
than unity. In cervical carcinoma cases, there were two (33%) cases
where E2 DNA was not detected. On the other hand, there were
four (67%) cases where the E2 DNA was detected, but the E2/E6
ratio was less than unity.
For 11 HPV-16-positive breast carcinoma specimens, we
examined the presence of HPV DNA in 1 specimen of
morphologically normal breast tissue adjacent to the carcinoma.
Human papillomavirus-16 DNA was detected in seven (64%) of
these specimens (Table 3). The geometric mean of viral load in the
normal tissue was 92 copies per 10
4 cells, which was higher than
that in breast carcinomas (5.4 copies per 10
4 cells); however, the
difference was not statistically significant (P¼0.162 by the
Mann–Whitney test). The analysis of the E2/E6 ratio in normal
epithelium specimens showed that in one (17%) case, E2 DNA was
not detected, and in four (66%) cases, E2 DNA was detected but
the E2/E6 ratio was less than unity. The remaining one (17%) case
had an E2/E6 ratio of approximately one. We also examined 11
normal breast specimens adjacent to HPV-negative breast tumor
tissue, but none of them was HPV-positive (Table 3). The
difference in HPV detection rates in surrounding normal mucosa
of HPV-positive and HPV-negative breast carcinoma cases was
statistically significant (P¼0.004 by Fisher’s exact test).
DISCUSSION
In this study, we found HPV DNA in 21% (n¼26) of
breast carcinomas in Japan. Another study conducted in Japan
detected HPV DNA in 11.1% of breast carcinomas (Yu et al, 1999).
High-risk types, such as HPV-16, -18, and -33, were detected in
our study. Despite great variability in the HPV detection rate
Table 2 HPV genotypes by INNO-LiPA and HPV-16 viral load and
physical status using real-time PCR in breast and cervical carcinoma
Viral load Integration
Sample
Genotype
by
INNO-LiPA
E6
copies
per 10
4
cells
E2
copies
per 10
4
cells E2/E6 Status
Breast cancer
BC-4 6, 16, 51 10 0 No E2 Integrated
BC-18 6, 16 4 0 No E2 Integrated
BC-19 16 28 0 No E2 Integrated
BC-27 6, 16 97 0 No E2 Integrated
BC-35 6, 16, 33, 51 3 0 No E2 Integrated
BC-42
a 6, 16
BC-44 6, 16 7184 0 No E2 Integrated
BC-60 6, 16 19 0 No E2 Integrated
BC-61 6, 18
BC-68 16 6 0 No E2 Integrated
BC-69 16 648 32 0.05 Mixed
BC-70 16 31 0 No E2 Integrated
BC-72
b o10 N o E2 Integrated
BC-78
b 66 0 N o E2 Integrated
BC-81 16 7 0 No E2 Integrated
BC-82 16 o10 N o E2 Integrated
BC-92 16 3 0 No E2 Integrated
BC-95
a 6, 16
BC-100 16 o10 N o E2 Integrated
BC-101
a 6, 16
BC-105 16 6 0 No E2 Integrated
BC-110 18
BC-112
b o10 N o E2 Integrated
BC-128
a 6, 16, 18
BC-131 16 4 0 No E2 Integrated
BC-132 16 o10 N o E2 Integrated
Cervical cancer
CX-2 16 8440 0 No E2 Integrated
CX-4 16 9159670 162656 0.018 Mixed
CX-7 16, 18, 68 1328 0 No E2 Integrated
CX-10 6, 16 82043 1181 0.014 Mixed
CX-11 6, 16 463450 1420 0.003 Mixed
CX-13 16 1264077 17343 0.014 Mixed
aThe template DNAs could not be amplified by both E6- and E2-specific primers for
HPV-16.
bThese cases were HPV-16-negative by the INNO-LiPA genotyping kit.
Table 3 HPV genotypes by INNO-LiPA and HPV-16 viral load and
physical status in surrounding normal epithelium of HPV-positive and HPV-
negative breast carcinoma cases
Viral load Integration
Sample
Genotype by
INNO-LiPA
E6
copies
per 10
4 cells
E2
copies
per 10
4 cells E2/E6 Status
HPV-positive
N-4 Negative
N-18 Negative
N-68 16 301 133 0.44 Mixed
N-69 16 3206 32 0.05 Mixed
N-70 16 25 o1 0.025 Mixed
N-72 Negative
N-78 16 14972 0 No E2 Integrated
N-82 16 o1 o1 1 Episomal
N-100 Negative
N-105 16 4 2 0.49 Mixed
N-112 16
aa
HPV-negative
N-19 Negative
N-50 Negative
N-55 Negative
N-57 Negative
N-65 Negative
N-66 Negative
N-92 Negative
N-94 Negative
N-95 Negative
N-102 Negative
N-108 Negative
HPV¼human papillomavirus.
aThere was not enough DNA template for this assay.
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sworldwide, the majority of HPV types that are detected are the
oncogenic types, HPV-16 and -18 (Di Lonardo et al, 1992; Hennig
et al, 1999; Liu et al, 2001; Damin et al, 2004; Kan et al, 2005). Our
results are in agreement with these previous reports. The
association of high-risk HPV was reported to be stronger in
invasive carcinomas (Yasmeen et al, 2007b). In this study,
however, the HPV frequency in invasive carcinomas was higher
than that of non-invasive carcinomas although the difference was
not statistically significant (P¼0.279).
The physical status of HPV-16 was determined by the HPV-16
E2/E6 ratio in this study. When the ratio was equal to or higher
than unity, all of the HPV-16 genome was considered to be in the
episomal form. Note, however, the E2/E6 ratio of unity or larger
does not necessarily deny the possibility of HPV integration
because HPV integration does not always cause E2 disruption
(Vernon et al, 1997; Eriksson et al, 1999). However, as we found no
breast carcinoma with the exclusive presence of episomal HPV-16
(E2/E6 ratio being equal to or higher than unity), this assumption
does not affect the interpretation of our observations. On the other
hand, the lack of amplified HPV-16 E2 genome was considered to
indicate the integration of all of the HPV-16 DNA into the host
genome. When the E2/E6 ratio was larger than zero and smaller
than unity, this condition was considered as a mixture of episomal
and integrated forms (Peitsaro et al, 2002). We found HPV-16
DNA integrated into the host genome in all HPV-16-positive breast
carcinoma cases, although one case harboured both integrated and
episomal forms of HPV-16. In cervical cancer samples, 67% of the
samples had HPV-16 in a mixed form, where HPV existed in both
episomal and integrated forms, and 33% of the samples had only
the integrated form of HPV. To our knowledge, this is the first
study reporting the physical status of HPV-16 in breast cancer
tissues.
In this study, the HPV-16 viral load determined by quantitative
real-time PCR in breast carcinoma was with a geometric mean of
5.4 per 10
4 cells, which was much lower than that observed in
cervical cancer (geometric mean¼130480). It is unlikely, however,
that the low viral loads in breast carcinoma specimens were a
consequence of formalin fixation and/or heating during paraffin
embedding, as a higher viral load was detected in formalin-fixed
and paraffin-embedded specimens of cervical cancer obtained
from the same institute. Moreover, we performed parallel
amplification of a housekeeping gene (b-globin) to obtain an
estimate of the amount of amplifiable genomic DNA in each
sample, and to help reconcile the inhibitory effects of formalin
fixation and paraffin embedding on DNA amplification.
A low copy number of HPV-16 in non-genital carcinomas has
also been reported in studies of Chilean lung carcinomas (Aguayo
et al, 2007) and Chinese oesophageal cancer (Shuyama et al, 2007)
conducted by our laboratory, and in a Finish study on head and
neck cancer (Koskinen et al, 2003). It should also be noted that
SiHa cells, which are a cervical cancer cell line, contain only 1–2
copies of HPV-16 per cell. Such a low copy number of HPV DNA in
SiHa cells suggests that a viral load as low as 1 copy per cell may be
sufficient to promote carcinogenesis, especially if the viral DNA is
integrated into the host cell genome (Si et al, 2005). In this study,
however, the viral load in breast carcinoma was much lower than 1
copy per cell. As breast cancer is considered a monoclonal
expansion and the integrated HPV genome is unlikely to disappear
from the host genome during cell replication, at least one copy of
integrated HPV is expected to be present in all carcinoma cells
even if only a copy of integrated HPV is sufficient for its
aetiological involvement. Therefore, even though HPV-16 was
found integrated in breast cancer cells in this study, its extremely
low viral load suggests that HPV-16 DNA is unlikely to be involved
in the development of those breast carcinomas.
In this study, HPV-16 was also found in 64% of normal mucosal
specimens adjacent to HPV-16-positive tumors but not in the non-
malignant epithelia from HPV-16-negative tumors. The presence
of HPV-16, not only in breast carcinomas but also in adjacent
normal tissue, can also be explained by the infection of HPV in
carcinomas after their development because both carcinoma and
adjacent normal tissue are likely to be exposed to such an
infection.
Hormonal factors (namely, oestrogen, and its derivatives) are
known to be involved in breast carcinogenesis (Pike et al, 1993).
Oestrogen receptor-positive breast carcinomas are more sensitive
to tamoxifen, an antioestrogen. An interesting question is whether
oestrogen-related breast cancer is strongly related to HPV. In this
regard, Hennig et al (1999) and Damin et al (2004) reported that
the presence of oestrogen or progesterone receptor was not related
to HPV presence in breast carcinomas. We also did not observe
any significant association of HPV presence with oestrogen and
progesterone receptor expression.
Approximately 25–30% of all breast cancers have an amplifica-
tion of the HER2/neu gene or overexpression of its protein product
(Slamon et al, 1987). Yasmeen et al (2007a) reported that E6/E7 of
HPV-16 cooperates with the HER2/neu receptor to induce breast
tumorigensis and metastasis. This study, however, did not show
any evidence indicating that HPV presence affects the relationship
between HER2/neu overexpression and tumor invasiveness.
We did not find any difference in the average age at diagnosis
between HPV-positive and HPV-negative breast cancers. Similar
results were described in studies of Norwegian and Brazilian
women (Hennig et al, 1999; Damin et al, 2004). In contrast,
Kroupis et al (2006) and Lawson et al (2006) demonstrated that the
average age of women with HPV-positive breast cancer is
significantly younger than women with HPV-negative breast
cancer, suggesting that sexual activity is one of the risk factors
of HPV-positive breast cancer.
In cervical cancer, the cytopathic effect of HPV infection is well
known as koilocytosis. There are several studies reporting similar
histological features among non-genital cancers (Miller et al, 1997;
Al-Qahtani et al, 2007). Although we reviewed haematoxylin–
eosin staining slides of all HPV-positive cases, none of them
showed pathological features of HPV infection such as koilocytes
(data not shown).
The transmission route of HPV detected in breast carcinoma is
yet unclear. Two independent studies suggested possible hemato-
genic and/or lymphatic transfer of the virus from one organ to
another (Hennig et al, 1999; Widschwendter et al, 2004).
Interestingly, the study by Hennig et al (1999) detected HPV-16
DNA in 46% of breast cancer occurring among women with a
history of high-grade cervical intraepithelial neoplasia (CIN III).
Their finding suggests that HPV-associated cervical neoplasia
might be the original site of HPV infection from which the virus
could be transported to the breast. In our study, there were four
breast cancer cases with a history of cervical cancer but only 1 of
them was HPV-positive in their breast tumors. de Villiers et al
(2005) showed HPV presence in the nipple, suggesting HPV
transfer in a retrograde fashion from the nipple via areola,
lactiferous ducts, and sinuses.
The reported prevalence of HPV infection in breast cancer
shows a great variation worldwide, ranging from 0 to 86% (Hennig
et al, 1999; Damin et al, 2004; de Villiers et al, 2005; Kan et al, 2005;
Kroupis et al, 2006; Choi et al, 2007; Lindel et al, 2007; Yasmeen
et al, 2007b). Demographic features and genetic backgrounds
may contribute to the geographical difference of HPV prevalence
in breast carcinomas worldwide. In addition, the difference in
published reports may be attributed to the numbers of samples
tested, methodological differences, and the sensitivity of methods
used, such as use of different primer sets. In this study, the use
of HPV-16-specific primers detected three additional HPV-16-
positive cases, which were HPV-16-negative by SPF10-PCR,
although the SPF10 primer set is considered highly sensitive. The
discrepancy between the SPF10 consensus primer set PCR and
PCR with HPV-16-specific primers stems from the fact that SPF10
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sprimers target the sequence of the L1 gene, which may be lost
during the integration of HPV-16 into the host genome (Noffsinger
et al, 1995; Karlsen et al, 1996).
In summary, HPV DNA was detected in 26 (21%) breast
carcinomas and, in all HPV-16-positive cases, the HPV genome
was considered to be integrated into the host genome. However,
their extremely low viral loads suggest that it is unlikely that
integrated HPV-16 is aetiologically involved in the development of
Japanese breast cancer cases examined in this study. As reported
by Shuyama et al (2007), the role of HPV in non-genital cancer
may vary in different study areas. Therefore, in the case of breast
cancer, we cannot deny the possibility that HPV may play a
significant role in breast cancer development in other countries.
Further studies are warranted to elucidate the aetiological role and
pathogenesis of HPV in breast cancer.
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